Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1968 1
1973 1
1977 1
1982 1
1984 2
1986 1
1987 3
1989 2
1990 3
1991 2
1998 2
2000 5
2002 1
2004 1
2006 1
2009 1
2011 1
2012 1
2013 1
2014 3
2015 2
2016 8
2017 8
2018 6
2019 7
2020 6
2021 9
2022 7
2023 7
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: chapuis ag. Blood. 2021 Jan 21;137(3):323-335. doi: 10.1182/blood.2020006770. Blood. 2021. PMID: 32967009 Free PMC article. Clinical Trial.
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, Koelle DM, Pierce RH, Bielas JH, Greenberg PD, Bhatia S, Gottardo R, Nghiem P, Chapuis AG. Paulson KG, et al. Among authors: chapuis ag. Nat Commun. 2018 Sep 24;9(1):3868. doi: 10.1038/s41467-018-06300-3. Nat Commun. 2018. PMID: 30250229 Free PMC article.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Hirayama AV, et al. Among authors: chapuis ag. Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19. Blood. 2019. PMID: 30782611 Free PMC article. Clinical Trial.
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG, Egan DN, Bar M, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gottardo R, Ragnarsson GB, Bleakley M, Yeung CC, Muhlhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath MJ, Duerkopp N, Gooley TA, Greenberg PD. Chapuis AG, et al. Nat Med. 2019 Jul;25(7):1064-1072. doi: 10.1038/s41591-019-0472-9. Epub 2019 Jun 24. Nat Med. 2019. PMID: 31235963 Free PMC article.
Immunotherapy for skin cancer.
Paulson KG, Lahman MC, Chapuis AG, Brownell I. Paulson KG, et al. Among authors: chapuis ag. Int Immunol. 2019 Jul 13;31(7):465-475. doi: 10.1093/intimm/dxz012. Int Immunol. 2019. PMID: 30753483 Free PMC article. Review.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. Cowan AJ, et al. Among authors: chapuis ag. Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2. Lancet Oncol. 2023. PMID: 37414012 Clinical Trial.
Genome Editing in Engineered T Cells for Cancer Immunotherapy.
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Bonini C, et al. Among authors: chapuis ag. Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128. Hum Gene Ther. 2023. PMID: 37694593 Review.
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, Voillet V, Martin L, Gottardo R, Bielas J, McElrath JM, Stirewalt DL, Pogosova-Agadjanyan EL, Yeung CC, Pierce RH, Egan DN, Bar M, Hendrie PC, Kinsella S, Vakil A, Butler J, Chaffee M, Linton J, McAfee MS, Hunter DS, Bleakley M, Rongvaux A, Van den Eynde BJ, Chapuis AG, Greenberg PD. Lahman MC, et al. Among authors: chapuis ag. Sci Transl Med. 2022 Feb 9;14(631):eabg8070. doi: 10.1126/scitranslmed.abg8070. Epub 2022 Feb 9. Sci Transl Med. 2022. PMID: 35138909 Free PMC article.
The Anticancer Potential of T Cell Receptor-Engineered T Cells.
Ecsedi M, McAfee MS, Chapuis AG. Ecsedi M, et al. Among authors: chapuis ag. Trends Cancer. 2021 Jan;7(1):48-56. doi: 10.1016/j.trecan.2020.09.002. Epub 2020 Sep 26. Trends Cancer. 2021. PMID: 32988787 Free PMC article. Review.
94 results